Should You Consider Investing in Poseida Therapeutics, Inc. (PSTX) After the Golden Cross?

From a technical standpoint, Poseida Therapeutics, Inc. (PSTX) is drawing attention as it has recently encountered a significant level of support. The stock's 50-day simple moving average has crossed above its 200-day simple moving average, which is a phenomenon referred to as a "golden cross" in the finance world.

A golden cross is often interpreted as a promising indicator for a bullish breakout. This technical pattern forms when the short-term moving average of a stock surpasses its long-term moving average. The typical crossover situation includes the 50-day and 200-day moving averages, as trends over longer durations are generally deemed more reliable.

There are three main phases involved in a golden cross. Initially, there is a downtrend in the stock's price, which eventually reaches a low point. Following this, the shorter moving average crosses above the longer moving average, signaling a potential uptrend. The final phase is characterized by the stock maintaining its upward trajectory towards higher price levels.

In contrast to a golden cross is the death cross, which signals the possible emergence of bearish momentum.

Over the past month, shares of PSTX have surged by an impressive 292%. Moreover, the company's current standing as a #2 (Buy) on the Zacks Rank indicates that PSTX may be in line for a breakout.

The bullish argument becomes even more compelling when factoring in PSTX's favorable earnings outlook for the current quarter. In the previous 60 days, there have been three upward revisions to earnings estimates, with none going lower, contributing to the increased Zacks Consensus Estimate as well.

Given the significant technical indicators and the positive shift in earnings estimates, investors should consider adding PSTX to their watchlist.

stocks, investment, trading